Skip to main content
. 2015 Jun 9;75(10):1049–1058. doi: 10.1007/s40265-015-0417-7

Fig. 3.

Fig. 3

Schematic representation of changes in the levels of biochemical markers of bone turnover during treatment with subcutaneous injections of either teriparatide (TPTD, 20 ug daily) or romosozumab (ROMO, 210 mg once monthly) for 1 year. Bone formation and bone resorption were assessed by measuring serum levels of procollagen type 1 aminoterminal propeptide (P1NP) and carboxy-terminal collagen crosslinking (CTX), respectively. Reproduced from [41]